It’s important to follow guidance on prostate-specific antigen screening that maximizes benefits and minimizes potential harms such as overdiagnosis and overtreatment.

Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023, according to NHS data. It’s also the second-deadliest form of the ...

To check for possible prostate cancer, physicians most often use prostate-specific antigen (PSA) tests and digital rectal exams (DREs). For a firm diagnosis, they use core needle biopsies. This page ...

There have been renewed calls for the introduction of a national screening programme for prostate cancer in the UK. Former British prime minister Rishi Sunak, actors and sportspeople have joined a ...

For asymptomatic people without known risks, the downsides and uncertainties of multi-cancer early detection testing could ...

While many people are familiar with mammograms and smear tests, prostate screening is talked about far less.To shed light on this important subject ahead of Prostate Cancer Awareness Month in March, ...

Private companies are capitalizing on this quest for information. Grail’s Galleri blood test screens for more than 50 different types of cancer from a single blood draw, while full-body MRI scans, ...

A urine-based biomarker panel detected prostate cancer in 91% of specimens with a diagnostic accuracy of 78.6% to 85.7%, according to a study published Sept. 2 in eBioMedicine. Led by a team from ...

The study's testing accurately identified prostate cancer 91% of the time and accurately ruled out men without prostate cancer 84% of the time. A urine-based biomarker panel may be a promising, ...

A new blended genome genetic test being studied in a major clinical trial may help identify men at highest risk of aggressive prostate cancer and personalise screening strategies.

Prostate Cancer Survivor, Jerry McCormick, urges Black men 45 years and older to get screened as soon as possible, because early detection could save their life.